ILUSTRASI. More than half of the 1,4 billion China population have so far received a non-mRNA booster shot. REUTERS/Aly Song
Sumber: Reuters | Editor: Anastasia Lilin Yuliantina
KONTAN.CO.ID - BEIJING. A Covid-19 vaccine candidate from China's Walvax Biotechnology using mRNA technology triggered a stronger antibody response against the Omicron variant of the coronavirus as a booster dose than Sinovac's shot. Clinical trial data showed.
The result for Walvax's ARCoV candidate, which is yet to be peer reviewed, comes as competition for the Covid booster market intensifies in China, where more than half of the 1,4 billion population have so far received a non-mRNA booster shot.
Agar bisa lanjut membaca sampai tuntas artikel ini, pastikan Anda sudah berlangganan atau membeli artikel ini.
Sudah berlangganan? Masuk
Berlangganan Hanya dengan 20rb/bulan Anda bisa mendapatkan berita serta analisis ekonomi, bisnis, dan investasi pilihan
Hanya Rp 5.000 untuk membaca artikel ini
Anda dapat menggunakan akun Google sebagai metode pembayaran karena Google akan mengingat metode yang sudah pernah digunakan.
